Ayala Pharmaceuticals Inc

NASDAQ:AYLA  
9.85
-0.03 (-0.30%)
Other Pre-Announcement

Ayala Pharma Reports Q3 Loss Per Share $0.59

Published: 11/17/2020 13:30 GMT
(AYLA) - Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Loss per Share $0.59.
Q3 Earnings per Share Estimate $-0.54 -- Refinitiv Ibes Data (analyst estimates).
Expects Its Existing Cash Balance to Fund Operations Into Second Half of 2022.
Qtrly Cash and Cash Equivalents Were $48.8 Million As of September 30, 2020, As Compared to $16.7 Million As of December 31, 2019.
On Track to Initiate Phase 2 Clinical Trial of Al102 for Treatment of Desmoid Tumors in First Half of 2021.
On Track to Initiate Phase 2 Clinical Trial of Al101 in H2 of 2021.